摘要
目的探讨孟鲁司特钠联合沙美特罗替卡松治疗小儿支气管哮喘的临床效果及对免疫功能、信号转导与转录激活因子1(STAT1)、干扰素调控因子1(IRF1)的影响。方法选择2019年10月至2020年12月我院接收的86例支气管哮喘患儿作为研究对象,根据治疗方案将其分为对照组和观察组,各43例。对照组给予沙美特罗替卡松治疗,观察组在对照组治疗方案基础上加施孟鲁司特钠治疗。比较两组的治疗效果。结果观察组的咳嗽缓解时间、哮鸣音消失时间、喘息缓解时间、住院时间短于对照组(P<0.05)。治疗后,观察组的白细胞分化抗原4阳性(CD4^(+))、白细胞分化抗原4阳性/白细胞分化抗原8阳性(CD4^(+)/CD8^(+))高于对照组,白细胞分化抗原8阳性(CD8^(+))低于对照组(P<0.05)。治疗后,观察组的IRF1、STAT1相对表达量低于对照组(P<0.05)。治疗后,观察组的肿瘤坏死因子-α(TNF-α)、白细胞介素-33(IL-33)、1-磷酸鞘氨醇(S1P)、解整合素-金属蛋白酶33(ADAM33)水平低于对照组(P<0.05)。结论孟鲁司特钠联合沙美特罗替卡松治疗小儿支气管哮喘的临床效果满意,能有效改善患儿的免疫功能,还能调节机体STAT1、IRF1相对表达量。
Objective To investigate the clinical effect of montelukast sodium combined with salmeterol fluticasone in the treatment of bronchial asthma in children and its influences on immune function,signal transducers and activators of transcription 1(STAT1)and interferon regulatory factor 1(IRF1).Methods A total of 86 children with bronchial asthma received in our hospital from October 2019 to December 2020 were selected as the research objects.According to the treatment plan,the children were divided into control group and observation group,with 43 cases in each group.The control group was treated with salmeterol fluticasone,and the observation group was treated with montelukast sodium on the basis of the treatment plan of the control group.The therapeutic effects of the two groups were compared.Results The cough relief time,wheezing disappearance time,wheezing relief time and hospitalization time in the observation group were shorter than those in the control group(P<0.05).After treatment,the cluster of differentiation 4 positive(CD4^(+))and cluster of differentiation 4 positive/cluster of differentiation 8 positive(CD4^(+)/CD8^(+))in the observation group were higher than those in the control group,and the cluster of differentiation 8 positive(CD8^(+))was lower than that in the control group(P<0.05).After treatment,the relative expression of IRF1 and STAT1 in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-33(IL-33),sphingosine 1-phosphate(S1P)and a disintegrin and metalloproteinase 33(ADAM33)in the observation group were lower than those in the control group(P<0.05).Conclusion Montelukast sodium combined with salmeterol fluticasone in the treatment of bronchial asthma in children has a satisfactory clinical effect.It can effectively improve the immune function of children,regulate the relative expression of STAT1 and IRF1.
作者
车蓬丽
崔文兰
CHE Pengli;CUI Wenlan(Baoji Maternal and Child Health Care Hospital,Baoji 721000;Shaanxi Sengong Hospital,Xi'an 710300,China)
出处
《临床医学研究与实践》
2022年第28期77-80,共4页
Clinical Research and Practice
关键词
孟鲁司特钠
沙美特罗替卡松
小儿
支气管哮喘
免疫功能
montelukast sodium
salmeterol fluticasone
children
bronchial asthma
immune function
